You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Bulk Pharmaceutical API Sources for NEMBUTAL SODIUM


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for NEMBUTAL SODIUM

Vendor Vendor Homepage Vendor Sku API Url
AKos Consulting & Solutions ⤷  Start Trial AKOS005111157 ⤷  Start Trial
TCI (Tokyo Chemical Industry) ⤷  Start Trial P0776 ⤷  Start Trial
Mcule ⤷  Start Trial MCULE-2611041665 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Nembutal Sodium (Pentobarbital Sodium)

Last updated: February 20, 2026

Reliable sources for purchasing Nembutal Sodium (pentobarbital sodium) bulk active pharmaceutical ingredient (API) are limited due to strict international and national regulations controlling barbiturates.

Regulatory Status and Supply Restrictions

Nembutal Sodium is classified as a Schedule II controlled substance under the US Controlled Substances Act (CSA) and is strictly regulated elsewhere globally. Its manufacturing, distribution, and export are highly restricted.

Key Regulatory Bodies:

  • US Drug Enforcement Administration (DEA)
  • European Medicines Agency (EMA)
  • International Narcotics Control Board (INCB)

Manufacturers typically operate under strict licensing to produce and supply Nembutal Sodium.

Major API Manufacturers and Suppliers

Licensed API Manufacturers

Most API manufacturers producing pentobarbital sodium operate under pharmaceutical licensing with compliance to Good Manufacturing Practice (GMP). Due to regulations, many do not publicly list their product catalog or distribution channels.

Manufacturer Location Certification Notes
Lundbeck (Lundbeck R&D) Denmark GMP, DEA licensed Historically a primary manufacturer
SIGMA-Aldrich (Merck KGaA) Germany GMP Supplies pharmaceutical ingredients globally
Excipient and specialty chemical firms Various (e.g., China, India) ISO, GMP (if licensed) May produce under licensing; verify legality with regulator

Key Points:

  • Licensed and GMP-certified suppliers operate primarily in North America, Europe, and select Asian countries.
  • Many unlicensed suppliers exist online but pose significant legal and safety risks.

International Suppliers and Gray Market

Due to the drug's controlled status, illicit markets and "gray market" suppliers provide Nembutal Sodium. These sources are highly unpredictable, often illegal, and carry risks such as:

  • Product purity issues
  • Legal penalties
  • Suppressed or falsified documentation

Risks

  • Illegal procurement methods
  • Quality assurance failures
  • Legal repercussions for import/export violations

Legal Framework and Import Regulations

  • United States: Strictly controlled; only licensed entities may obtain and handle Nembutal Sodium. Import requires DEA registration and adherence to drug enforcement laws.
  • European Union: Classified as a controlled substance; import and distribution require compliance with national regulations enshrined in the EU's drug control policies.
  • Other jurisdictions: Varying degrees of control; typically require authorization from drug regulatory agencies.

Summary of API Sources

Source Type Availability Cost Legality
Licensed Manufacturers Limited to licensed buyers; GMP-certified Higher due to regulatory compliance Legal, with proper licensing
Distributors (licensed) Usually require proof of license Varies by supplier, typically higher Legal, with proper licensing
Gray Market Suppliers/Online vendors No verified legitimacy Potentially lower but risky Likely illegal; high risk

Conclusion

Sources for bulk Nembutal Sodium API are primarily limited to licensed, GMP-compliant manufacturers globally. Due to strict regulations, obtaining the API outside legal channels presents significant risks. Buyers must verify the supplier’s licensing status and adherence to regulatory standards.

Key Takeaways

  • Nembutal Sodium API is tightly controlled by law, restricting bulk distribution to licensed manufacturers.
  • Major regulated suppliers include Lundbeck and Merck KGaA.
  • Unregulated or illegal sources pose serious legal and safety risks.
  • Import is subject to national drug control laws; compliance is mandatory.
  • For research or clinical use, procurement must follow appropriate licensing procedures.

FAQs

1. Can I legally buy Nembutal Sodium API for research purposes?
Yes, but only through licensed, regulated suppliers and with compliance to local drug laws.

2. Who are the largest licensed manufacturers of Nembutal Sodium API?
Lundbeck (Denmark) and Merck KGaA (Germany) are primary licensed global producers.

3. Is it possible to import Nembutal Sodium API into the US?
Only authorized, DEA-licensed entities can import; personal importation is illegal.

4. How do online gray market vendors operate with Nembutal Sodium?
They often sell without proper licensing, posing legal and safety risks.

5. Are there alternative suppliers for similar barbiturates?
Yes, but all are regulated; acquiring such APIs requires proper licensing and regulatory approval.


References

  1. U.S. Drug Enforcement Administration. (2022). Schedule of Controlled Substances: 21 CFR 1240.14. https://www.deadiversion.usdoj.gov/21cfr/21cfr.pdf
  2. International Narcotics Control Board. (2021). Report of the International Narcotics Control Board for 2020.
  3. European Medicines Agency. (2022). Pharmaceutical legislation in the EU. https://www.ema.europa.eu/en/legislation
  4. Merck KGaA. (2023). Product catalog.
  5. Lundbeck A/S. (2023). Pharmaceutical API documentation.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.